Fingertips Practice Dashboard (PCN Comparison)
Selected practice
The Woodberry Practice
F85020
PCN: ENFIELD SOUTH WEST PCN
This view compares the selected practice with its PCN average using the same indicator, time period, and visible breakdown where available.
Indicators shown
49
Themes shown
1
Matched PCN rows
49
Average gap
-2.49
Board-ready messages
  • Smoking prevalence appears above PCN.
Top opportunities vs PCN
Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs)
Other | 2024/25
53.13
-25.68
Patients with severe mental health issues having a comprehensive care plan (denominator incl. PCAs)
Other | 2024/25
72.58
-12.62
For patients with stroke a record exists that an anti-platelet agent or an anti-coagulant is taken (denominator incl. PCAs)
Other | 2024/25
78.87
-10.83
Patients with heart failure due to LVSD treated with beta-blockers (denominator incl. PCAs)
Other | 2024/25
73.81
-10.17
Patients with heart failure who had a review in the last 12 months, including the assessment of functional capacity (denominator incl. PCAs)
Other | 2024/25
80.00
-9.14
Newly diagnosed patients with diabetes referred for an education programme within 9 months (denominator incl. PCAs)
Other | 2024/25
46.34
-8.66
Patients with Asthma: review in the last 12 months (denominator incl. PCAs)
Other | 2024/25
59.26
-8.42
Patients with psychosis who have a current record of alcohol consumption
Other | 2024/25
83.87
-6.78
Top strengths vs PCN
Patients with COPD with a MRC dyspnoea score >=3 in the last 12 months, who have had an offer of referral to a pulm. rehab. clinic (denominator incl. PCAs)
Other | 2024/25
46.43
+13.38
Last BP reading of patients (80+ yrs, with CHD) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs)
Other | 2024/25
91.55
+7.61
Dementia care plan has been reviewed in the last 12 months (denominator incl. PCAs)
Other | 2024/25
88.24
+5.76
Patients with diabetes and proteinuria/micro-albuminuria treated with ACE inhibitors (denominator incl. PCAs)
Other | 2024/25
81.58
+3.99
Percentage of broad-spectrum prescribed antibiotic items (cephalosporin, quinolone and co-amoxiclav class) by quarter
Other | 2025 Q3
14.52
+3.96
% reporting learning disability
Other | 2024
6.58
+3.93
% with a long-standing health condition (2024 definition)
Other | 2024
55.89
+1.59
% of patients reporting to suffer from 'long Covid'
Other | 2024
6.27
+1.34
72.35
Last BP in patients with diabetes is <= 140/80 mmHg (denominator incl. PCAs)
2024/25 | %
PCN: 77.82
Gap: -5.47
80.78
Last BP reading of patients (80+ yrs, with hypertension), in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs)
2024/25 | %
PCN: 81.27
Gap: -0.49
67.22
Last BP reading of patients (<80 yrs, with hypertension), in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)
2024/25 | %
PCN: 71.42
Gap: -4.20
46.34
Newly diagnosed patients with diabetes referred for an education programme within 9 months (denominator incl. PCAs)
2024/25 | %
PCN: 55.00
Gap: -8.66
53.13
Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs)
2024/25 | %
PCN: 78.81
Gap: -25.68
59.26
Patients with Asthma: review in the last 12 months (denominator incl. PCAs)
2024/25 | %
PCN: 67.68
Gap: -8.42
70.53
Patients with COPD who had a review in the last 12 months (denominator incl. PCAs)
2024/25 | %
PCN: 75.77
Gap: -5.24
46.43
Patients with COPD with a MRC dyspnoea score >=3 in the last 12 months, who have had an offer of referral to a pulm. rehab. clinic (denominator incl. PCAs)
2024/25 | %
PCN: 33.05
Gap: +13.38
PCN comparison bar chart
PCN: ENFIELD SOUTH WEST PCN
Comparison table
Indicator Theme Breakdown Time period Practice PCN Gap Unit
% active smokers (GPPS) Other 16+ yrs 2024 18.61 17.84 +0.78 %
% former smokers (GPPS) Other 16+ yrs 2024 19.77 22.02 -2.25 %
% of patients reporting to suffer from 'long Covid' Other 16+ yrs 2024 6.27 4.94 +1.34 %
% QOF points achieved Other Not applicable | Not applicable 2024/25 90.37 91.49 -1.12 %
% reporting a joint problem, such as arthritis Other 16+ yrs 2024 11.86 15.23 -3.38 %
% reporting a long-term mental health problem Other 16+ yrs 2024 5.05 9.98 -4.93 %
% reporting Alzheimer's disease or dementia Other 16+ yrs 2024 0.00 0.28 -0.28 %
% reporting blindness or partial sight Other 16+ yrs 2024 0.00 0.87 -0.87 %
% reporting deafness or hearing loss Other 16+ yrs 2024 3.57 3.27 +0.30 %
% reporting learning disability Other 16+ yrs 2024 6.58 2.65 +3.93 %
% reporting to be unemployed Other 16+ yrs 2024 7.61 6.46 +1.15 %
% with a long-standing health condition (2024 definition) Other 16+ yrs 2024 55.89 54.29 +1.59 %
% with caring responsibility Other 16+ yrs 2024 10.24 14.38 -4.15 %
Dementia care plan has been reviewed in the last 12 months (denominator incl. PCAs) Other All ages 2024/25 88.24 82.48 +5.76 %
Depression: QOF incidence - new diagnosis Other 18+ yrs 2024/25 1.36 1.35 +0.01 %
For patients with CHD, a record that aspirin, APT or ACT is taken exists (denominator incl. PCAs) Other All ages 2024/25 86.50 92.96 -6.46 %
For patients with stroke a record exists that an anti-platelet agent or an anti-coagulant is taken (denominator incl. PCAs) Other All ages 2024/25 78.87 89.70 -10.83 %
Heart failure w LVSD: treated with ACE-I or ARB (denominator incl. PCAs) Other All ages 2024/25 83.33 82.48 +0.85 %
Last BP in patients with diabetes is <= 140/80 mmHg (denominator incl. PCAs) Other 17+ yrs 2024/25 72.35 77.82 -5.47 %
Last BP reading of patients (80+ yrs, with a history of stroke or TIA) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) Other 80+ yrs 2024/25 82.22 84.26 -2.04 %
Last BP reading of patients (80+ yrs, with CHD) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) Other 80+ yrs 2024/25 91.55 83.93 +7.61 %
Last BP reading of patients (80+ yrs, with hypertension), in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) Other 80+ yrs 2024/25 80.78 81.27 -0.49 %
Last BP reading of patients (<80 yrs, with a history of stroke or TIA) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) Other <80 yrs 2024/25 73.61 72.41 +1.20 %
Last BP reading of patients (<80 yrs, with CHD) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) Other <80 yrs 2024/25 77.11 82.78 -5.67 %
Last BP reading of patients (<80 yrs, with hypertension), in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) Other <80 yrs 2024/25 67.22 71.42 -4.20 %
Life expectancy - MSOA based Other Female | All ages 2019 - 23 86.19 85.79 +0.40 Years
Newly diagnosed patients with depression who had a review 10-56 days after diagnosis (denominator incl. PCAs) Other 18+ yrs 2024/25 77.38 78.68 -1.30 %
Newly diagnosed patients with diabetes referred for an education programme within 9 months (denominator incl. PCAs) Other 17+ yrs 2024/25 46.34 55.00 -8.66 %
Patients with AF who are treated w anti-coag. therapy (CHADS2DS2-VASc >=2) (denominator incl. PCAs) Other All ages 2024/25 90.48 89.53 +0.95 %
Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) Other 6-19 yrs 2024/25 53.13 78.81 -25.68 %
Patients with Asthma: review in the last 12 months (denominator incl. PCAs) Other 6+ yrs 2024/25 59.26 67.68 -8.42 %
Patients with COPD who had a review in the last 12 months (denominator incl. PCAs) Other All ages 2024/25 70.53 75.77 -5.24 %
Patients with COPD with a MRC dyspnoea score >=3 in the last 12 months, who have had an offer of referral to a pulm. rehab. clinic (denominator incl. PCAs) Other All ages 2024/25 46.43 33.05 +13.38 %
Patients with diabetes (40+ yrs, no history of CVD) treated with a statin (denominator incl. PCAs) Other 40+ yrs 2024/25 73.03 77.61 -4.58 %
Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) Other 17+ yrs 2024/25 84.32 89.44 -5.11 %
Patients with diabetes and proteinuria/micro-albuminuria treated with ACE inhibitors (denominator incl. PCAs) Other 17+ yrs 2024/25 81.58 77.59 +3.99 %
Patients with diabetes who had a foot examination and risk classification (denominator incl. PCAs) Other 17+ yrs 2024/25 72.96 74.35 -1.39 %
Patients with heart failure due to LVSD treated with beta-blockers (denominator incl. PCAs) Other All ages 2024/25 73.81 83.98 -10.17 %
Patients with heart failure who had a review in the last 12 months, including the assessment of functional capacity (denominator incl. PCAs) Other All ages 2024/25 80.00 89.14 -9.14 %
Patients with psychosis who have a current record of a lipid profile Other All ages 2024/25 83.87 88.06 -4.19 %
Patients with psychosis who have a current record of alcohol consumption Other All ages 2024/25 83.87 90.65 -6.78 %
Patients with severe mental health issues having a comprehensive care plan (denominator incl. PCAs) Other All ages 2024/25 72.58 85.20 -12.62 %
Patients' heart failure diagnosis confirmed by an ECG or specialist assessment (denominator incl. PCAs) Other All ages 2024/25 88.89 90.41 -1.53 %
Percentage of broad-spectrum prescribed antibiotic items (cephalosporin, quinolone and co-amoxiclav class) by quarter Other All ages 2025 Q3 14.52 10.56 +3.96 %
Record of offer of support and treatment in the last 24 months for smokers aged 15+ yrs (denominator incl. PCAs) Other 15+ yrs 2024/25 90.46 92.83 -2.36 %
Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) Other All ages 2024/25 97.76 97.71 +0.05 %
Smoking status of patients with certain conditions recorded in the last 12 months (denominator incl. PCAs) Other All ages 2024/25 87.84 93.20 -5.36 %
Stroke risk of patients with AF assessed with CHA2DS2-VASc (denominator incl. PCAs) Other All ages 2024/25 93.78 98.21 -4.43 %
Total number of prescribed antibiotic items per STAR-PU by quarter - GP Other All ages 2025 Q3 0.19 0.14 +0.05 Number of items prescribed

Arjus |
2023 ©

v1.0